Response Biomedical Receives FDA 510(k) Clearance of Rapid Influenza A+B Test
go back to news archives Response Biomedical Corporation has received FDA 510(k) clearance to market a rapid Influenza A+B test (Flu A+B test) and a new version of the RAMP® Reader, the RAMP® 200. The test manufactured by Response Biomedical runs on the new RAMP® 200 Reader and will be marketed and sold worldwide exclusively by 3M Health Care as the 3M™ Rapid Detection Flu A+B Test. It is a qualitative immunochromatographic assay indicated for use as an in vitro diagnostic product with the 3M™ Rapid Detection Reader (manufactured by Response) to identify the presence of Flu A and Flu B nucleoprotein antigen in nasopharyngeal swab, nasopharyngeal aspirate, nasal wash/aspirate specimens. Measurement of Flu A and Flu B aids in the rapid differential diagnosis of influenza viral infections through use of this test. 3M Health Care anticipates launching prior to the 2008-09 flu season in certain markets around the world. |
NOTE: This item is from our 'historic' database and
may contain information which is not up to date.
Source : Response Biomedical Corp. View Company Information
Posted on April 22, 2008
LATEST MICROBIOLOGY NEWS
MICROBIOLOGY EVENTS
-
Getting Equipped for the Future with the New MAS-100 Sirius® Microbial Air Sampler
1 Jul 2025 -
AI for Food Safety Professionals
8 Jul 2025 -
FEMS Micro
14 Jul 2025 -
Unmasking Endotoxins: A Sample Preparation Strategy to Overcome LER
15 Jul 2025 -
IAFP 2025
27 Jul 2025 -
ADLM 2025
27 Jul 2025 -
Food Safety Culture Workshop
9 Sep 2025 -
CPD accredited course: Level 3 HACCP & Food Safety
15 Sep 2025 -
Culture Eats HACCP for Breakfast (free)
On-demand Webinar -
A3P International Congress 2025
7 Oct 2025